Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Capital
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 22, 2020
The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.